ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Sulfonium-Driven Neoantigen-Released DNA Nanodevice as a Precise Vaccine for Tumor Immunotherapy and Prevention

Zhang, Yaping; Xu, Hongkun; Jiang, Leying; Liu, Zhaodi; Lian, Chenshan; Ding, Xiaofeng; Wan, Chuan; Liu, Na; Wang, Yuena; Yu, Zhiqiang; Zhu, Lizhi*; Yin, Feng*; Li, Zigang*安徽医科大学; 南方医科大学; 1
ACS Nano2022-11-22DOI: 10.1021/acsnano.2c09708
8被引16阅读
引用收藏
分享

摘要

Peptide-based neoantigen vaccines hold tremendous potential for personalized tumor immunotherapy. However, effective delivery and controllable release of antigen peptides remain major challenges in stimulating robust and sustained immune responses. Programmable DNA nanodevices provide accurate fixed positions for antigens, which are convenient for the calculation of clinical dosage, and hold great potential as precise carriers. Here, a peptide-nucleic acid conjugate was prepared, which was driven by a propargyl sulfonium-based efficient and reversible bio-orthogonal reaction under weakly alkaline conditions, and folded into regular DNA nanodevice vaccines. The well-defined nanoplatform not only exhibits outstanding stability in serum, satisfactory safety, and effective internalization by antigen-presenting cells (RAW264.7 and BMDCs) but also obviously enhances cytokine (TNF alpha, IL-6, and IL-12) secretion for further immune response. In vivo, the nanovaccine cooperating with OVA model antigens and CpG adjuvants stimulated an antigen-specific CD8+T cell response, significantly preventing the lung metastases of melanoma. In the B16-OVA tumor-bearing model, the growth inhibition rate of melanoma reached up to 50%. Similarly, the DNA nanodevice with neoantigen induced up to a maximum degree of complete MC-38 tumor regression in 80% of mice, possibly owing to antigen peptide reversible release driven by sulfonium and further cross-presentation. In brief, this study demonstrates that DNA nanodevices with sulfonium centers can provide a precise, biocompatible, and effective co-delivery vaccine platform for tumor immunotherapy and prevention.

学科与关键词

关键词
DNA-peptide conjugationsulfoniumDNA nanodeviceimmunotherapyimmune prevention
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
ACS Nano
发表日期
2022-11-22
卷期
第 16 卷, 第 11 期
页码
19509-19522
DOI
10.1021/acsnano.2c09708
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [21778009, 21977010]; Key Technologies Research and Development Program of China [2018YFA0902504]; Natural Science Foundation of Guangdong Province [2019A1515110365, 2019A1515111184, 2020A1515010522]; Science, Technology and Innovation Commission of Shenzhen Municipality [JCYJ20180507181-527112, JCYJ201805081522131455, JCYJ20200109140406047]; Shenzhen Key Medical Discipline Construction Fund [SZXK060]; Beijing National Laboratory of Molecular Science open grant [BNLMS20160112]; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions grant [2019SHIBS0004]

作者

  • Z

    Zhang, Yaping (第一作者)

    peking univ, shenzhen grad sch

  • X

    Xu, Hongkun

    peking univ, shenzhen grad sch

查看全部 13 位作者收起作者
  • J

    Jiang, Leying

    peking univ, shenzhen grad sch

  • L

    Liu, Zhaodi

    1 · anhui med univ

  • L

    Lian, Chenshan

  • D

    Ding, Xiaofeng

    1 · anhui med univ

  • W

    Wan, Chuan

    peking univ, shenzhen grad sch

  • L

    Liu, Na

    peking univ, shenzhen grad sch

  • W

    Wang, Yuena

    peking univ, shenzhen grad sch

  • Y

    Yu, Zhiqiang

    new · southern med univ

  • Z

    Zhu, Lizhi (通讯)

    1 · 2 · shenzhen univ

  • Y

    Yin, Feng (通讯)

  • L

    Li, Zigang (通讯)

    peking univ, shenzhen grad sch

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417